Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR T) therapy has demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma, and now there are two US Food and Drug Administration-approved BCMA-directed CAR T products. However, despite high in...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
Main Authors:	Oliver Van Oekelen, Karthik Nath, Tarek H. Mouhieddine, Tasmin Farzana, Adolfo Aleman, David T. Melnekoff, Yogita Ghodke‐Puranik, Gunjan L. Shah, Alexander M. Lesokhin, Sergio Giralt, Santiago Thibaud, Adriana Rossi, Cesar Rodriguez, Larysa Sanchez, Joshua Richter, Shambavi Richard, Hearn Jay Cho, Ajai Chari, Saad Z. Usmani, Sundar Jagannath, Urvi A. Shah, Sham Mailankody, Samir Parekh
פורמט:	Artigo
שפה:	אנגלית
יצא לאור:	2022
גישה מקוונת:	https://doi.org/10.1182/blood.2022017848 https://ashpublications.org/blood/article-pdf/141/7/756/2034470/blood_bld-2022-017848-main.pdf
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

אינטרנט

https://doi.org/10.1182/blood.2022017848
https://ashpublications.org/blood/article-pdf/141/7/756/2034470/blood_bld-2022-017848-main.pdf

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

אינטרנט

פריטים דומים